Advaxis Enrolls Patients to Cervical Cancer Vaccine Trial.

NORTH BRUNSWICK, N.J. -- The first cancer patients to be treated with an engineered live Listeria vaccine were dosed in Advaxis Inc. (OTCBB: ADXS) Phase I/II clinical trial of Lovaxin C, a Listeria-based therapeutic cancer vaccine developed to treat cervical cancer. Several additional patients are being screened. The trial, taking place in Serbia, Israel and Mexico, will enroll 20 cervical cancer patients and is expected to last approximately six months, with the fundamental objective to demonstrate the safety of Lovaxin C.

This is the first human study by Advaxis in its proposed development of a new class of cancer therapies. These therapies use modified Listeria to deliver a tumor specific antigen, which together have the ability to generate a robust immune response involving multiple integrated immune mechanisms and is characterized by high levels of tumor-infiltrating cytotoxic T cells.

It is expected that this "first in man" trial of a live Listeria cancer vaccine will demonstrate the ability to give therapeutic concentrations of Lovaxin C safely.

About Advaxis

Based in North Brunswick, New Jersey. Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis' is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis is entering a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.